HIV-infection and comorbidities: a complex mix

In *The Lancet HIV*, Line Rasmussen and colleagues report time trends in the risk of a range of severe age-related morbidities in HIV-positive and HIV-negative individuals in Denmark. The investigators noted increased risk of these morbidities in HIV-positive people compared with that in HIV-negative matched controls. However, this increased risk did not substantially increase with age; therefore, suggesting no greater increased risk effect of ageing in HIV-positive people than in HIV-negative populations. Similar findings have been reported in other studies. Data from the Veterans Aging Cohort Study Virtual Cohort (VACS) showed an increased risk of myocardial infarction, end-stage renal disease, and non-AIDs defining cancers in HIV-positive veterans; however, these events occurred at similar ages as in HIV-negative veterans. In the D:A:D study, the increasing risk of cardiovascular disease, coronary heart disease, and myocardial infarction with increasing age was similar to that predicted from conventional cardiovascular risk equations such as the Framingham equation. Similarly, the results of the AGEnHIV Cohort Study of some of these comorbidities in both HIV-positive and HIV-negative people showed an increased prevalence in HIV-positive individuals, with little evidence of a differing effect with age.

For most of the comorbidities, Rasmussen and colleagues did not note substantial increases with increasing duration of HIV infection or duration on antiretroviral therapy. The causes of these long-term clinical outcomes in HIV-positive individuals are a complex mix of HIV infection, antiretroviral treatment, co-infections such as hepatitis B and hepatitis C virus, and lifestyle factors such as cigarette smoking and use of alcohol and other drugs, which are much more prevalent in people with HIV than in those without. As in most other studies, Rasmussen and colleagues were unable to tell whether the HIV virus, its treatment, co-infections, or social-behavioural factors contributed to the increased risk of the age-related morbidities in HIV-positive individuals. Many studies of the comparison of HIV-positive and HIV-negative populations without data for co-infection and lifestyle factors have this limitation. Data from well matched HIV-positive and HIV-negative prospective cohort studies with detailed information about HIV, treatment, co-infection, and social behavioural or lifestyle factors are needed to find out which of the factors increase the risk of age-related morbidities; however, such studies would need large numbers of participants with long follow-up.

One particularly interesting finding from Rasmussen and colleagues’ analyses is a consistent pattern of declining relative risk of these age-related comorbidities with increasing age. The most likely explanation of this effect is a survivor bias, whereby HIV-positive patients most at risk of these events do not survive to older age. These patients are likely to be individuals who do not respond well to antiretroviral treatment, have detectable viral load, and have low CD4-positive cell counts, which are associated with an increased risk of all causes of death. Therefore, the most important factor for ensuring good health of HIV-positive individuals is early antiretroviral treatment, leading to long-term undetectable viral load.

The changes in the morbidity profile of ageing HIV-positive individuals have important implications for their management and treatment. For many people, HIV infection has now become a long-term manageable chronic illness, with the new challenge being the prevention and management of chronic illnesses that occur at increased rates. Understanding the contribution of HIV infection, antiretroviral treatment, and lifestyle factors to the development of these comorbidities in HIV-positive individuals could have a substantial effect on the design of the best screening and prevention strategies. In the absence of large prospective studies, the key steps to ensure healthy ageing in HIV-positive individuals are first treat patients early to achieve and maintain undetectable HIV viral load, and second reduce the prevalence of many of the traditional risk factors for the ageing-related morbidities, particularly smoking, which is probably the largest modifiable risk factor in HIV-positive patients.

*Kathy Petoumenos, Matthew Law
Kirby Institute, UNSW Australia, Sydney, NSW 2052, Australia (KP, ML)
kpetoumenos@kirby.unsw.edu.au
KP and ML have received unrestricted research funding from ViV Healthcare, Bristol-Myers Squibb, Gilead Sciences, Janssen Cilag, Merck Sharp and Dohme, and Boehringer Ingelheim.

Published Online
May 28, 2015
http://dx.doi.org/10.1016/S2352-3018(15)00082-X
See Articles page e288


